Abstract
In a placebo-controlled study, denileukin diftitox (DD) was effective against cutaneous T-cell lymphoma (CTCL) expressing CD25. An open-label companion study examined the efficacy and safety of DD in 36 patients with skin biopsies containing < 20% CD25 cells by immunohistochemistry staining (CD25 low expression). Patients received DD 18 μg/kg/day for 5 consecutive days every 3 weeks for up to eight courses. The primary endpoint, overall response rate, was 30.6% (95% confidence interval: 16.3, 48.1), 33.3% for stage IIA or lower disease, and 26.7% for stage IIB or greater disease. Median progression-free survival (PFS) was > 487 days, and median time to treatment failure was 68.5 days. No difference in PFS by disease stage was observed. The safety profile of DD in CD25 low-expression disease was similar to that in CD25+ disease. These findings suggest that CD25 low expression does not preclude a meaningful clinical response to DD in patients with CTCL.
Original language | English |
---|---|
Pages (from-to) | 69-75 |
Number of pages | 7 |
Journal | Leukemia and Lymphoma |
Volume | 54 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2013 |
Keywords
- Antigens
- CD25
- Cutaneous T-cell lymphoma
- Denileukin diftitox
- Mycosis fungoides
- Sézary syndrome